BCAT-IN-4 Secrets
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review to evaluate several intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Main demo aims had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis pat